Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering

About this update from Kiniksa Pharmaceuticals International, Plc

[{"type":"text","content":"HAMILTON, Bermuda, July 20, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced today that it is commencing a public offering of $100.0 million of Class A common shares. In addition, Kiniksa expects to grant the underwriters a 30-day option to purchase up to $15.0 million of additional Class A common shares. All of the Class A common shares are being offered by Kiniksa.\n Kiniksa intends to use the net proceeds from the offering to advance the development of its product candidates, to advance commercialization activities and to fund other research and development activities as well as for working capital and general corporate purposes. Goldman Sachs & Co. LLC, BofA Securities and J.P. Morgan are acting as joint book-running managers for the offering. Kiniksa has filed a registration statement (including a prospectus) with the U.S. Securities and Exchange Commission (the “SEC”) for the offering to which this communication relates, which was declared effective on June 10, 2019. Before you invest, you should read the prospectus in that registration statement and other documents Kiniksa has filed with the SEC for more complete information about Kiniksa and the offering. You may get these documents for free by visiting EDGAR on the SEC’s website located at www.sec.gov. A preliminary prospectus supplement related to the offering (including the accompanying prospectus) will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus may also be obtained, when available, from Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, New York 10282, or by telephone at (866) 471-2526, or via email at [email protected]; BofA Securities, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255, Attention: Prospectus Department, or via email at [email protected]; and J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, via telephone: (866) 803-9204, or via email at [email protected]. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or j...

More updates from Kiniksa Pharmaceuticals International, Plc